---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-078023"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2026-06-26T12:43:39+00:00"
generated_at: "2026-06-26T12:45:12.901071+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Celldex shareholders OK 3.4M share increase to equity plan; all directors re-elected

## Summary
- Approved 2021 Omnibus Equity Incentive Plan amendment raising share reserve by 3.4M to 12.9M shares.
- All nine director nominees elected, including CEO Anthony Marucci and Chair Harry Penner Jr.
- Ratification of PwC as independent auditor for FY 2026 passed with 64.7M for vs 174.7K against.
- Advisory say-on-pay proposal approved: 59.2M for, 945K against, 479.7K abstain.
- Plan amendment also clarifies tax withholding provisions for equity awards.

## SEC filing metadata
- accession: 0001104659-26-078023
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2026-06-26T12:43:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465926078023/0001104659-26-078023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465926078023/tm2619009d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-078023
- JSON: https://secwatch.observer/filing/0001104659-26-078023.json
- Plain text: https://secwatch.observer/filing/0001104659-26-078023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.